Jump to content



Recommended Posts

  • Replies 809
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

  • 4 weeks later...
Interesting announcement out today saying that Avexa have renegotiated their deal with Shire by issuing Shire with $5 million worth of new shares. They provide little additional detail, but do say that they believe this will result in "...a reduction of sales royalties and removal of future milestone payments." Think about that..... Shire have agreed to take additional equity in the company at its current share price while giving up milestone payments and royalties. What is in it for Shire? They are giving up longer term benefits in the form of royalties for more shares. One might interpret that to mean that Shire see the chance for a greater short term return on owning more shares directly. The benefit for Avexa of course is that they get the longer term benefits of reduced royalties etc. This smells very much like a takeover is in the wind (note the provision to hold the shares in escrow for 12mo unless there is a change of ownership). Avexa didn't have to make this deal and neither did Shire. The only way both parties come out of this a winner is if Avexa gets taken over soon! Time to buy!
Link to comment
Share on other sites

  • 2 weeks later...

Cut and pasted from someone over at the other channel. I agree with the thoughts and added to my position today. Time will tell if it was a smart move.


Appears certainly Circadian(CIR) selling out remaining AVX holding now that they have taken 100% ownership of Vegenics. Some extracts of their Half Yearly Report to 31/12/07 posted below. As they effectively came into a lot of AVX shares at 25 cents, it is not hurting them to unload them at this level. Suggest very good buying for us!!!

"The current period includes a net gain on the sale of 5.6 million ordinary shares in Avexa Limited of
$2,575,377 which includes the recovery of impairment losses recognised prior to 1 July 2005 of $1,633,108
(CircadianÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s remaining holding is 8,087,914 ordinary shares)."


Link to comment
Share on other sites

In reply to: dee27 on Friday 12/09/08 07:51pm

thanks for the info dee,

i were in bit of shock to see someone dump the stock like trash. if it's CIR, that will be no major effect to what AVX can achieve their goals.


if it goes down to the bottom of the sea, then i will sink with this little boat!! http://www.sharescene.com/html/emoticons/weirdsmiley.gif



Link to comment
Share on other sites

  • 2 weeks later...

Notice received this morning... shifts within the Board with a focus on M&A....


Nathan Drona now Chairman.

Addition of David Bottomly who has background in M&A and capital market transactions, and Alan Boyd (CFO).


Looks like we're one step closer and Avexa is positioning for the end game!


"We are transitioning to a key period as ATC's Phase 3 trial advances and the balance of the pipeline business begins to mature. To this end it is imperative to strengthen our leadership team with expertise in business development and M&A as we look to maximise the potential of ATC" said Julian Chick CEO.


Good news... DL

Link to comment
Share on other sites

From The Australian:


Avexa (AVX) is in a phase III trial for its HIV drug Apricitabine and Neuren (NEU) has a phase III trial under way in the US for its brain-protective drug Glypromate.


Both have been savaged by investors and are woefully undervalued. So much so that they represent either 20-baggers or are in danger of going out the back door.


Full story:





Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...